CS
OCUL icon

Candriam SCA’s Ocular Therapeutix OCUL Stock Holding History

Candriam SCA’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.91M Sell
907,839
-41,377
-4% -$375K 0.04% 300
2026
Q1 		$8.04M Buy
949,216
+107,614
+13% +$1.03M 0.04% 317
2025
Q4 		$10.2M Buy
+841,602
New +$10.2M 0.05% 266

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Candriam SCA's OCUL Position: Q2 2026 in Review

Candriam SCA reduced its Ocular Therapeutix (OCUL) stake by 4.4% in Q2 2026, selling an estimated $375K and leaving 907,839 shares worth $8.91M. The position accounts for 0.04% of the portfolio, ranked #300.

Candriam SCA first reported a position in OCUL in Q4 2025 and has held it in 3 quarters since. The position peaked at $10.2M in Q4 2025. 263 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Candriam SCA held 907,839 shares of Ocular Therapeutix worth $8.91M as of Q2 2026.
  • Candriam SCA sold 41,377 Ocular Therapeutix shares in Q2 2026, an estimated $375K.
  • Ocular Therapeutix made up 0.04% of Candriam SCA's portfolio in Q2 2026, its #300 holding.
  • Candriam SCA first reported a position in Ocular Therapeutix in Q4 2025 and has held it in 3 quarters since.
  • Candriam SCA's Ocular Therapeutix position peaked at $10.2M in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.